Form 4: Collegium Pharmaceutical Director Nancy Lurker Reports Stock Grant and Disposal

Director Nancy Lurker reports acquisition of restricted stock units and disposal of common stock.

Summary

• On May 15, 2025, Nancy Lurker, a director of Collegium Pharmaceutical, Inc., acquired 9,791 shares of common stock through restricted stock units (RSUs).
• These RSUs were granted at a price of $0.
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical's common stock.
• The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, contingent upon continued service with the Issuer.
• The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
• Following the transaction, Lurker directly owns 22,517 shares of Collegium Pharmaceutical, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The grant of restricted stock units to a director aligns their interests with those of the shareholders.

Future Outlook

The RSUs will vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's holdings and alignment with company performance.

Key Dates

Keywords

Form 4, Director, Stock, Collegium Pharmaceutical, Nancy Lurker, RSU, Restricted Stock Units, Beneficial Ownership